Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167)
Hong Kong
· Delayed Price · Currency is HKD 7.05
-0.09 (-1.26%)
Apr 29, 2026, 4:08 PM HKT
HKG:1167 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Revenue | 53.53 | 155.71 | 63.52 | 95.75 | 152.81 | Upgrade
|
| Revenue Growth (YoY) | -65.63% | 145.13% | -33.66% | -37.34% | -68.58% | Upgrade
|
| Cost of Revenue | 0.59 | - | 60.32 | 83.11 | 139.98 | Upgrade
|
| Gross Profit | 52.93 | 155.71 | 3.2 | 12.63 | 12.83 | Upgrade
|
| Selling, General & Admin | 34.43 | 43.05 | 46.62 | 42.55 | 44.58 | Upgrade
|
| Research & Development | 188.59 | 330.18 | 372.32 | 445.65 | 280.84 | Upgrade
|
| Other Operating Expenses | -3.84 | -14.33 | -3.78 | 5.36 | -20.27 | Upgrade
|
| Operating Expenses | 219.17 | 358.89 | 415.16 | 493.56 | 305.14 | Upgrade
|
| Operating Income | -166.24 | -203.19 | -411.95 | -480.93 | -292.31 | Upgrade
|
| Interest Expense | -12.94 | -8.4 | -8.31 | -2.27 | -0.57 | Upgrade
|
| Interest & Investment Income | 31.7 | 40.86 | 47.07 | 24.61 | 18.77 | Upgrade
|
| Earnings From Equity Investments | -0.53 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -16.24 | 12.19 | 20.69 | 82.53 | -27.26 | Upgrade
|
| EBT Excluding Unusual Items | -164.25 | -158.53 | -352.51 | -376.05 | -301.38 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.9 | -0.02 | -7.24 | 4.19 | 0.19 | Upgrade
|
| Gain (Loss) on Sale of Assets | 19.17 | -0.14 | 0.63 | - | - | Upgrade
|
| Other Unusual Items | - | 2.98 | - | - | - | Upgrade
|
| Pretax Income | -145.98 | -155.71 | -359.12 | -371.86 | -301.19 | Upgrade
|
| Earnings From Continuing Operations | -145.98 | -155.71 | -359.12 | -371.86 | -301.19 | Upgrade
|
| Net Income | -145.98 | -155.71 | -359.12 | -371.86 | -301.19 | Upgrade
|
| Net Income to Common | -145.98 | -155.71 | -359.12 | -371.86 | -301.19 | Upgrade
|
| Shares Outstanding (Basic) | 775 | 775 | 773 | 752 | 747 | Upgrade
|
| Shares Outstanding (Diluted) | 775 | 775 | 773 | 752 | 747 | Upgrade
|
| Shares Change (YoY) | -0.04% | 0.26% | 2.79% | 0.61% | 96.13% | Upgrade
|
| EPS (Basic) | -0.19 | -0.20 | -0.46 | -0.49 | -0.40 | Upgrade
|
| EPS (Diluted) | -0.19 | -0.20 | -0.46 | -0.49 | -0.40 | Upgrade
|
| Free Cash Flow | - | -86.21 | -402.03 | -308.86 | -157.6 | Upgrade
|
| Free Cash Flow Per Share | - | -0.11 | -0.52 | -0.41 | -0.21 | Upgrade
|
| Gross Margin | 98.89% | 100.00% | 5.04% | 13.20% | 8.40% | Upgrade
|
| Operating Margin | -310.59% | -130.49% | -648.54% | -502.29% | -191.29% | Upgrade
|
| Profit Margin | -272.73% | -100.00% | -565.36% | -388.38% | -197.10% | Upgrade
|
| Free Cash Flow Margin | - | -55.37% | -632.92% | -322.58% | -103.13% | Upgrade
|
| EBITDA | -153.75 | -190.69 | -401.12 | -473.71 | -285.57 | Upgrade
|
| EBITDA Margin | -287.25% | -122.47% | - | - | -186.88% | Upgrade
|
| D&A For EBITDA | 12.49 | 12.49 | 10.83 | 7.21 | 6.74 | Upgrade
|
| EBIT | -166.24 | -203.19 | -411.95 | -480.93 | -292.31 | Upgrade
|
| EBIT Margin | - | -130.49% | - | - | -191.29% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.